home > ict > summer 2011 > five shows, one vision
International Clinical Trials

Five Shows, One Vision

Every year, pharma professionals get the chance to visit five exhibitions that attract experts, innovators and buyers from around the world – all in a single location. This year, CPhI Worldwide, ICSE, InnoPack, BioPh and P-MEC Europe will be held at the popular Messe Frankfurt exhibition centre in Germany, from 25th to 27th October


Since its launch in 1990 as an international convention on pharma ingredients with a modest 250 attendees, the show has grown rapidly to become the world’s biggest pharmaceutical exhibition and a ‘must attend’ event for pharma professionals.

Last year’s event, in Paris, was the biggest to date, attracting 28,897 attendees and more than 1,900 international exhibitors, including hundreds of firms making their debut. It’s an unbeatable opportunity to gain market knowledge, meet contacts and network with like-minded pharma executives. Many new products are launched, making the show ideal for catching up with the latest developments.


The event has been designed to deliver a larger, more comprehensive cross-section of the pharma industry under one roof – from ingredients and machinery through to contract services and packaging. The show is the perfect way to network with senior decision-makers from around the world.

As confidence returns to the global pharma industry, it’s never been more important to develop your network and build awareness of opportunities around the world. Each of the five shows, organised by UBM Live, is centered on a different aspect of the pharma industry.


For more than 20 years, CPhI Worldwide has been the world’s leading exhibition for firms involved in pharmaceutical ingredients. CPhI features zones devoted to APIs, generic APIs, custom manufacturing, fine chemicals, intermediates, finished dosage, and excipients/formulation.


International Contract Services Event (ICSE) connects the pharmaceutical community with outsourcing solution providers, offering a forum for business development, networking and education. According to a recent report from Global Industry Analysts, the global pharmaceutical contract manufacturing market is expected to reach $40.7 billion by 2015, driven by the continued need to cut costs. This clearly demonstrates that outsourcing is more important than ever.

This year, ICSE is focused on Clinical Trials and Contract Research, as well as Logistics and Supply Chain. The ICT l 97 Clinical Trials zone incorporates preclinical trials, clinical research, Phase 1 to 4 clinical trials and contract research organisations.


InnoPack is a new addition for 2011, created as a result of the success of ICSE’s Packaging Zone. It brings together buyers and specifiers from the packaging and pharmaceutical industries, creating business opportunities through a dedicated worldwide forum.

InnoPack offers innovative and diverse solutions to meet the increasing demand for new ways to package and deliver medication. It features a special Labelling Zone, exclusively for firms providing labelling, anti-counterfeiting and trackand- trace solutions.


BioPh delivers a fresh focus on biotech as a key driver of innovation across the pharma industry. BioPh brings together the key players in this drive for innovation. Firms seeking new development partners for treatments and processes can network with senior decision-makers, including senior managers, suppliers, potential collaborators and regulatory experts from large pharma companies.


P-MEC covers every aspect of pharma and biotech equipment and technology, from packaging machinery, through laboratory and analytical techniques, to trackand- trace technologies. P-MEC was created to bring together buyers and sellers of equipment under the umbrella of the CPhI brand, covering areas such as instrumental analysis, measuring and testing technology, materials testing, packaging machinery, RFID and quality control. This year, a new LABWorld Pavilion caters specifically for professionals in the field of laboratory, analytical and biotechnology instrumentation.


CPhI’s Pre-Show Conference is a strategic forum aimed at understanding how the pharma industry can take advantage of new market developments and drive future competitive advantage in global sourcing and contracting. Held before the main CPhI exhibition opens on Monday 24th October, it will allow delegates to tap into the knowledge of more than 350 distinguished industry peers and influential thinkers from around the world. This year, the conference is split into six modules along two tracks:
  • Module A: global API sourcing strategies
  • Module B: the strategic and operational future of the pharmaceutical industry
  • Module C: contract partnership selection CMO, CRO and CRAMS
  • Module D: the challenges and opportunities in biosimilars and biobetters
  • Module E: supplier and partnership management in the growth and ‘pharmerging’ markets
  • Module F: analysing market growth in generics and super generics
Each module features a line-up of expert speakers from leading pharma firms including GSK, Pfizer, Roche, Boehringer-Ingelheim, Biogen Idec, AstraZeneca, Eli Lilly, Abbott, Eisai and many more.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:

There are no comments in regards to this article.


Print this page
Send to a friend
Privacy statement
News and Press Releases

Merck Becomes One of the First CDMOs to Provide Full Viral Vector Offering with Launch of VirusExpress® 293 Adeno-Associated Virus Production Platform

09 Aug 2022, Darmstadt, Germany: Merck, a leading science and technology company, has launched the VirusExpress® 293 Adeno-Associated Virus (AAV) Production Platform, making it one of the first CDMOs and technology-developers to provide a full viral vector manufacturing offering including AAV, Lentiviral, CDMO, CTO, and process development. This new platform enables biopharmaceutical companies to increase the speed to clinical manufacturing while reducing process development time and costs.
More info >>

White Papers

Quality By Design

Biopharma Group

Quality by Design (QbD) is a systematic approach to development that begins with the defined objectives and emphasizes science and quality risk management in order to achieve those goals. QbD ensures that the quality of the product is built into production processes from the outset, rather than being tested after development has already commenced.
More info >>




©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement